Brovana, and Lanreotide. Particularly, the easing of price erosion pressure in the base portfolio further contributes to Cipla's robust performance in the US, the report further said. In addition ...

Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...